Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

What Should You Avoid Before a PSA Test?

Latest Prostate Cancer News and Research

OncoAssure announces clinical validation of prostate cancer test

OncoAssure Ltd, an Irish medical diagnostic company, today announced the publication of new data, in the British Journal of Urology International Compass (BJUI Compass), which demonstrates the clinical validation of OncoAssure Prostate, a novel biopsy test which provides improved estimation of a patient’s risk of prostate cancer recurrence and allows for optimal treatment selection.

21 Jan 2025

Expert consensus provides unified framework for prostate cancer care in China

While prostate cancer is becoming more prevalent among middle-aged and elderly men in China, clinical practice still faces considerable challenges due to the lack of unified guidelines and high-level evidence on several aspects of patient care.

20 Jan 2025

Exploring the use of genomic classifier tests in prostate cancer risk stratification

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for better data on their cost-effectiveness, clinical utility, and their impact on racial and ethnic groups, particularly Black men.

20 Jan 2025

New resource from NCCN offers guidance on hereditary cancer risk

Today, the National Comprehensive Cancer Network (NCCN)-an alliance of leading cancer centers-published a new resource to inform people about the latest recommendations around hereditary and familial cancer risk.

16 Jan 2025

NCCN global meeting focuses on cancer care in the MENA region

The National Comprehensive Cancer Network (NCCN)-a global not-for-profit alliance of leading cancer centers-is taking part in a two-day meeting at the Middle East North Africa (MENA)-NCCN Regional Coordinating Center, beginning today.

11 Jan 2025

Machine learning reveals why cancer trials fall short in real-world patients

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients and enhancing research accuracy.

10 Jan 2025

RNA nanoparticles offer dual action against prostate tumors

Yang Zhang, PhD, and Jinjun Shi, PhD, both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer."

10 Jan 2025

Functional characterization of variants improves cancer risk assessment and treatment

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.

9 Jan 2025

New AI system aims to improve real-world application of clinical trial results

A new study led by Winship Cancer Institute of Emory University and Abramson Cancer Center of University of Pennsylvania researchers demonstrates that a first-of-its-kind platform using artificial intelligence (AI) could help clinicians and patients assess whether and how much an individual patient may benefit from a particular therapy being tested in a clinical trial.

8 Jan 2025

Researchers explore steam treatment for prostate cancer

Steam eliminates wrinkles and germs, but can it destroy cancer cells too?

7 Jan 2025

Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.

3 Jan 2025

Patient-centered reports help reduce worry and improve understanding of test results

In April 2021, a provision in the 21st Century Cures act took effect which required that all medical test results be released to a patient's electronic medical record as soon as they become available.

3 Jan 2025

LGBTQ+ people relive old traumas as they age on their own

Bill Hall, 71, has been fighting for his life for 38 years. These days, he's feeling worn out.

24 Dec 2024

Assessing the impact of gozetotide in PSMA-positive prostate cancer

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify patients for whom PSMA-targeted therapy with (177Lu)lutetium vipivotide tetraxetan ("Lutetium-177" for short) is an option.

20 Dec 2024

A novel approach to combatting prostate cancer

New research by a team of Indiana University School of Medicine scientists and their collaborators has uncovered a novel vulnerability in prostate cancer animal models that starves prostate tumors of critical nutrients and stunts their growth, which could lead to the development of new treatments for the deadly disease.

19 Dec 2024

Crafting concise and authoritative healthcare resources

Discover how S. Karger has positioned itself as a reference in the healthcare industry by publishing trusted content for 30 years.

From S. Karger AG 17 Dec 2024

Dinuclear platinum(II) complexes could offer a more targeted approach to treating prostate cancer

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men.

16 Dec 2024

Dietary adjustments may help control prostate cancer in men undergoing active surveillance

A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators offers new evidence that dietary changes may help reduce cancer cell growth in patients undergoing active surveillance, a treatment approach that involves regular monitoring of the cancer without immediate intervention.

14 Dec 2024

Study unveils key mechanism behind prostate cancer's uncontrolled growth

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers.

14 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024